Therapeutic Potential of HIV-1 Entry Inhibitor Peptidomimetics

Overview

Journal Exp Biol Med (Maywood)

Specialty Biology

Date 2021 Feb 18

PMID 33596698

Authors

Nneka Pu Korie

Kwesi Z Tandoh

Samuel K Kwofie

Osbourne Quaye

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus 1 (HIV-1) infection remains a public health concern globally. Although great strides in the management of HIV-1 have been achieved, current highly active antiretroviral therapy is limited by multidrug resistance, prolonged use-related effects, and inability to purge the HIV-1 latent pool. Even though novel therapeutic options with HIV-1 broadly neutralizing antibodies (bNAbs) are being explored, the scalability of bNAbs is limited by economic cost of production and obligatory requirement for parenteral administration. However, these limitations can be addressed by antibody mimetics/peptidomimetics of HIV-1 bNAbs. In this review we discuss the limitations of HIV-1 bNAbs as HIV-1 entry inhibitors and explore the potential therapeutic use of antibody mimetics/peptidomimetics of HIV-1 entry inhibitors as an alternative for HIV-1 bNAbs. We highlight the reduced cost of production, high specificity, and oral bioavailability of peptidomimetics compared to bNAbs to demonstrate their suitability as candidates for novel HIV-1 therapy and conclude with some perspectives on future research toward HIV-1 novel drug discovery.

References

Salazar G, Zhang N, Fu T, An Z . Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2017; 2:19. PMC: 5627241. DOI: 10.1038/s41541-017-0019-3. View

Arthos J, Cicala C, Martinelli E, Macleod K, Ryk D, Wei D . HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008; 9(3):301-9. DOI: 10.1038/ni1566. View

Pavet V, Portal M, Moulin J, Herbrecht R, Gronemeyer H . Towards novel paradigms for cancer therapy. Oncogene. 2010; 30(1):1-20. DOI: 10.1038/onc.2010.460. View

Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

Parray H, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C . Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020; 85:106639. PMC: 7255167. DOI: 10.1016/j.intimp.2020.106639. View

la Porte C . Saquinavir, the pioneer antiretroviral protease inhibitor. Expert Opin Drug Metab Toxicol. 2009; 5(10):1313-22. DOI: 10.1517/17425250903273160. View

Williams , Sinko . Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev. 2000; 39(1-3):211-238. DOI: 10.1016/s0169-409x(99)00027-7. View

Lee E, Owen M . The application of transgenic mice for therapeutic antibody discovery. Methods Mol Biol. 2012; 901:137-48. DOI: 10.1007/978-1-61779-931-0_8. View

Kaufmann D, Rosenberg E . The value of preserving HIV-specific immune responses. J HIV Ther. 2003; 8(1):19-25. View

10.

Karpas A, Hewlett I, Hill F, Gray J, Byron N, Gilgen D . Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A. 1990; 87(19):7613-7. PMC: 54798. DOI: 10.1073/pnas.87.19.7613. View

11.

Yeh K, Deutsch P, Haddix H, Hesney M, Hoagland V, Ju W . Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother. 1998; 42(2):332-8. PMC: 105409. DOI: 10.1128/AAC.42.2.332. View

12.

Andrianov A, Kashyn I, Tuzikov A . Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01. J Mol Graph Model. 2015; 61:262-71. DOI: 10.1016/j.jmgm.2015.08.003. View

13.

Firer M, Gellerman G . Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012; 5:70. PMC: 3508879. DOI: 10.1186/1756-8722-5-70. View

14.

Wang W, Singh S, Zeng D, King K, Nema S . Antibody structure, instability, and formulation. J Pharm Sci. 2006; 96(1):1-26. DOI: 10.1002/jps.20727. View

15.

Andrianov A, Kashyn I, Tuzikov A . Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency. J Bioinform Comput Biol. 2018; 16(2):1840007. DOI: 10.1142/S0219720018400073. View

16.

Vanhamel J, Bruggemans A, Debyser Z . Establishment of latent HIV-1 reservoirs: what do we really know?. J Virus Erad. 2019; 5(1):3-9. PMC: 6362902. View

17.

Lei J, Sun L, Huang S, Zhu C, Li P, He J . The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019; 11(7):3919-3931. PMC: 6684887. View

18.

Scheid J, Mouquet H, Feldhahn N, Walker B, Pereyra F, Cutrell E . A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2008; 343(2):65-7. PMC: 2754789. DOI: 10.1016/j.jim.2008.11.012. View

19.

Chen B . Molecular Mechanism of HIV-1 Entry. Trends Microbiol. 2019; 27(10):878-891. PMC: 6744290. DOI: 10.1016/j.tim.2019.06.002. View

20.

Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman A, Lampiris H . Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359(14):1442-55. DOI: 10.1056/NEJMoa0803154. View